Faron, etusivu

releases and publications

First Patient Dosed in Phase II/III COVID-19 Trial

Regulatory

Notice of Half-Year Report

Regulatory

Faron to Host KOL Webinar on the Potential of Clever-1 Receptor as a Target for Macrophage-Guided Immunotherapy on July 19, 2021

Updated corporate presentation

Regulatory

Bexmarilimab granted key US patent

Regulatory

Bexmarilimab results published in CCR

Regulatory

Bexmarilimab shows promising anti-tumour activity

Regulatory

US rights to patent related to Traumakine

Regulatory

Holding(s) in Company

Shareholder announcement Regulatory

Grant of options

Insider Transaction Regulatory
PreviousNext
Back to top